Cockayne Syndrome

Cockayne syndrome is a rare genetic condition that affects many parts of the body. It is characterized by poor growth, a smaller than average head size, and delayed development. Children with this condition often appear to age prematurely and are very sensitive to sunlight, though they do not have an increased risk of skin cancer. The condition is caused by changes in genes that help the body repair damaged DNA. The syndrome has a significant impact on vision and hearing. Most patients develop a condition called pigmentary retinopathy, where the light-sensitive tissue at the back of the eye breaks down over time, leading to vision loss. They may also develop cataracts (clouding of the eye's lens) and optic nerve damage. Hearing loss is also very common and worsens as the child gets older. Cockayne syndrome is a progressive condition, meaning symptoms get worse over time. The severity and how quickly symptoms appear can vary greatly from person to person. While there is currently no cure, treatments focus on managing symptoms, such as using hearing aids, physical therapy, sun protection, and special education to improve the child's quality of life.

Condition category: Syndromic IRD

Prevalence: 1 in 250,000

Inheritance patterns: Autosomal Recessive

Age of onset: Variable, ranging from prenatal/birth (Type II/COFS) to early childhood (Type I, typically <2 years) or late childhood (Type III, >2 years).

Clinical overview: Cockayne syndrome (CS) is a rare, multisystem, autosomal recessive genetic disorder characterized by progressive growth failure, microcephaly, neurodevelopmental delays, premature aging, cutaneous photosensitivity, and sensorial impairment. It belongs to a family of nucleotide excision repair (NER) disorders, sharing some molecular pathways with xeroderma pigmentosum and trichothiodystrophy, but distinctively lacking an increased risk of skin cancer. The clinical spectrum of Cockayne syndrome is continuous but is generally classified into several subtypes based on the age of onset and severity. Type I (classic CS) presents in early childhood; Type II (severe CS) presents at birth with little postnatal development; Type III (mild CS) presents later in childhood with a slower progression; and Cerebrooculofacioskeletal (COFS) syndrome represents the most severe, prenatal form of the disease. Ophthalmological manifestations are a prominent feature of the disease, including progressive pigmentary retinopathy, optic atrophy, and cataracts. The progressive neurological deterioration, characterized by a "tigroid" pattern of demyelination in the brain, leads to severe disability and premature death. The relevant OMIM numbers include 133540 (CSB) and 216400 (CSA), and the Orphanet number is ORPHA:191.

Patient and family guide: Cockayne syndrome is a rare genetic condition that affects many parts of the body. It is characterized by poor growth, a smaller than average head size, and delayed development. Children with this condition often appear to age prematurely and are very sensitive to sunlight, though they do not have an increased risk of skin cancer. The condition is caused by changes in genes that help the body repair damaged DNA. The syndrome has a significant impact on vision and hearing. Most patients develop a condition called pigmentary retinopathy, where the light-sensitive tissue at the back of the eye breaks down over time, leading to vision loss. They may also develop cataracts (clouding of the eye's lens) and optic nerve damage. Hearing loss is also very common and worsens as the child gets older. Cockayne syndrome is a progressive condition, meaning symptoms get worse over time. The severity and how quickly symptoms appear can vary greatly from person to person. While there is currently no cure, treatments focus on managing symptoms, such as using hearing aids, physical therapy, sun protection, and special education to improve the child's quality of life.

Symptoms and clinical features: The clinical presentation of Cockayne syndrome is progressive and varies by subtype. In the early stages of classic Type I, prenatal growth is normal, but growth failure becomes evident within the first two years of life. Infants may present with weak cry, poor feeding, and delayed developmental milestones. Cutaneous photosensitivity may be noted early on. In the severe Type II, growth failure and congenital cataracts are present at birth, with little to no postnatal neurologic development. As the disease progresses to the intermediate stages, patients develop a characteristic facial appearance often described as "cachectic dwarfism" with sunken eyes, a thin nose, and large ears. Neurological symptoms become prominent, including intellectual disability, cerebellar ataxia, spasticity, and peripheral neuropathy. Sensorineural hearing loss begins and progressively worsens. Ophthalmological issues manifest, including pigmentary retinopathy, optic atrophy, and enophthalmos. Dental anomalies, such as severe caries and delayed eruption, are also common. In the advanced stages, there is severe, unremitting neurologic deterioration. Patients often lose the ability to walk and may develop joint contractures (arthrogryposis). Incontinence, tremors, seizures, and loss of speech can occur. Brain imaging reveals progressive cerebral and cerebellar atrophy with diffuse hypomyelination and basal ganglia calcifications. The progressive loss of vision and hearing leads to profound sensory isolation before premature death.

Molecular pathology: Cockayne syndrome is primarily a disorder of DNA repair, specifically affecting the transcription-coupled nucleotide excision repair (TC-NER) pathway. This subpathway is responsible for the rapid removal of bulky DNA lesions, such as those induced by ultraviolet (UV) light or oxidative stress, from the actively transcribed strands of expressed genes. The ERCC8 gene encodes the CSA protein, which contains WD repeats and functions as part of an E3 ubiquitin ligase complex. The ERCC6 gene encodes the CSB protein, an SNF2-family DNA-dependent ATPase. Both proteins are recruited to sites where RNA polymerase II is stalled by DNA damage. They facilitate the remodeling of the chromatin and the recruitment of other NER factors to excise the lesion and repair the DNA. Mutations in ERCC6 or ERCC8 lead to defective TC-NER, resulting in the accumulation of DNA damage, prolonged stalling of RNA polymerase II, and subsequent apoptosis or cellular senescence. In addition to their role in DNA repair, CSA and CSB are implicated in basal transcription, oxidative stress response, and mitochondrial function. The failure to repair oxidative DNA damage in post-mitotic cells, such as neurons, is thought to be a primary driver of the progressive neurodegeneration and premature aging phenotype seen in Cockayne syndrome, distinguishing it from other NER disorders like xeroderma pigmentosum, which are characterized by cancer predisposition.

Genetics: Cockayne syndrome is inherited in an autosomal recessive manner. It is caused by biallelic pathogenic variants in one of two major genes: ERCC6 (also known as CSB), located on chromosome 10q11, which accounts for approximately 65-75% of cases; and ERCC8 (also known as CSA), located on chromosome 5q12.1, which accounts for about 25-35% of cases. To date, no clear genotype-phenotype correlations have been definitively established for ERCC6 or ERCC8, as the syndrome spans a continuous phenotypic spectrum. However, some studies suggest that individuals with pathogenic variants in ERCC8 may have slightly less severe manifestations at the time of diagnosis compared to those with ERCC6 variants. For ERCC6, variants upstream of a specific transposon insertion in intron 5 have been associated with less severe features than those downstream. The genetic heterogeneity of Cockayne syndrome is further complicated by its overlap with other DNA repair disorders. Some rare individuals present with a combined Xeroderma pigmentosum-Cockayne syndrome (XP-CS) complex, which can be caused by mutations in other NER genes such as ERCC1, ERCC2 (XPD), ERCC3 (XPB), ERCC4 (XPF), and ERCC5 (XPG).

Diagnostic evaluation: The diagnosis of Cockayne syndrome is established in a proband by identification of biallelic pathogenic variants in the ERCC6 or ERCC8 genes. Clinical diagnostic workup includes a thorough neurological, dermatological, and ophthalmological evaluation. Differential diagnosis includes other nucleotide excision repair disorders like xeroderma pigmentosum and trichothiodystrophy, as well as mitochondrial diseases that may show similar clinical features. Ophthalmological workup reveals characteristic findings. Fundoscopy typically shows a progressive pigmentary retinopathy, often described as a "salt-and-pepper" type, with narrowed retinal arterioles and optic atrophy. In older patients, typical bone spicule formation may be observed. Congenital cataracts are a hallmark of the severe forms (Type II and COFS). Optical coherence tomography (OCT) demonstrates thinning of the retinal layers, particularly affecting the external retinal layers and foveal ellipsoid zone abnormalities. Electroretinography (ERG) is typically abnormal, showing reduced or absent responses, especially in rods, indicating widespread retinal dysfunction. Visual field testing may show progressive loss corresponding to the retinal degeneration.

Differential diagnosis: Differential diagnosis of Cockayne syndrome includes: (1) Xeroderma pigmentosum — photosensitivity and neurodegeneration but with skin cancers; some complementation group overlap. (2) Trichothiodystrophy — photosensitivity, brittle hair, ichthyosis, intellectual impairment. (3) Seckel syndrome — dwarfism, microcephaly, but no photosensitivity or retinal dystrophy. (4) Progeria (Hutchinson-Gilford) — premature aging but different mechanism (LMNA mutations). (5) Mitochondrial disorders — neurodegeneration with retinal findings but different imaging and biochemical profile.

Natural history: The natural history of Cockayne syndrome varies significantly depending on the subtype. In Type I (classic), prenatal growth is normal, but growth and development fall below normal within the first two years of life. This is followed by progressive impairment of vision, hearing, and central and peripheral nervous system function. The mean age of death for Type I is 16 years, typically occurring in the first or second decade. Type II (severe) presents with growth failure at birth and little to no postnatal neurologic development. Congenital cataracts are common. Affected children experience rapid progression and typically die by age 5 to 7 years. Cerebrooculofacioskeletal (COFS) syndrome represents the most extreme prenatal form, with severe findings identifiable during fetal life and early mortality. Type III (mild) has a later onset, with major features becoming apparent after age two. These individuals experience a slower rate of decline and may survive into adulthood. Across all types, the presence of early cataracts is considered a significant negative prognostic factor.

Management and treatment research: ### Current Management and Standard of Care There is currently no cure for Cockayne syndrome and no treatment proven to slow or reverse the underlying disease process. Care is individualized and usually coordinated among multiple specialists to support comfort, nutrition, mobility, communication, and quality of life. Management may include: - **Nutrition and feeding support:** Feeding difficulties, poor growth, and failure to thrive are common. Dietitians and feeding specialists may recommend calorie-rich supplements, texture-modified foods, swallowing support, or tube feeding, including gastrostomy feeding when needed. - **Physical, occupational, and speech therapy:** These services may help maintain mobility and joint range of motion, address stiffness or contractures, support daily activities, and assist with communication, swallowing, and feeding. - **Hearing and vision care:** Regular hearing and eye assessments are important. Sensorineural hearing loss may be supported with hearing aids and communication strategies. Ophthalmology care may address cataracts, retinal changes, dry eye, and other eye concerns. - **Sun and skin protection:** Photosensitivity can cause significant skin reactions after sun exposure. Protective clothing, hats, shade, and sunscreen can help limit exposure. - **Neurologic and musculoskeletal care:** Clinicians may use standard treatments for seizures, spasticity, pain, scoliosis, and movement-related concerns. Mobility aids, seating adaptations, orthopedic care, and other supportive equipment may be helpful. - **Dental and general medical care:** Regular dental care is important because tooth decay can be severe. Monitoring may include growth, kidney function, blood pressure, swallowing, breathing, and other concerns based on the individual’s symptoms. - **Palliative and supportive care:** Palliative care can be involved alongside other medical care at any stage to help manage symptoms, support family decision-making, and address practical and emotional needs. ### Approved Therapies No disease-modifying therapies are currently approved specifically for Cockayne syndrome. Treatment remains focused on managing symptoms and preventing or treating complications. ### Investigational Research Cockayne syndrome is caused by changes in genes involved in DNA repair, including transcription-coupled repair. This process helps cells respond to certain types of DNA damage. Research is working to better understand how these genetic changes lead to neurologic, developmental, eye, hearing, and other multisystem features. There are currently no interventional treatment trials or investigational therapy programs in the available pipeline for Cockayne syndrome. Current research opportunities are primarily natural-history studies, registries, and biobanking projects. These studies collect information about symptoms, disease progression, genetic findings, and biological samples. They do not test a treatment, but they may help researchers prepare for future clinical trials. ### Clinical Trial Participation Families may wish to discuss research participation with their genetics or specialty care team. Studies that may include people with Cockayne syndrome or related rare conditions include: - **NCT05484570** — *Natural History Study for DNA Repair Disorders*; recruiting, University of Minnesota. - **NCT03047369** — *The Myelin Disorders Biorepository Project*; recruiting, Children’s Hospital of Philadelphia. - **NCT01793168** — *Rare Disease Patient Registry & Natural History Study – Coordination of Rare Diseases at Sanford*; recruiting, Sanford Health. - **NCT06938542** — *Palliative Care Needs of Children With Rare Diseases and Their Families*; enrolling by invitation, Children’s National Research Institute. Eligibility, travel requirements, study procedures, and whether a study is appropriate vary by participant and study site.

Outlook: The prognosis for Cockayne syndrome is generally poor and depends heavily on the specific subtype. In classic Type I, progressive, unremitting neurologic deterioration leads to severe disability, with death typically occurring in the first or second decade of life (mean age 16 years). Type II has a much worse prognosis, with death usually occurring by age 5 to 7 years. Individuals with Type III may survive into adulthood. Quality of life is significantly impacted by progressive vision and hearing loss, loss of mobility, and cognitive decline. The presence of early cataracts is a strong indicator of a more severe disease course. Management requires a multidisciplinary approach to provide supportive care, maximize comfort, and address complications as they arise.

Epidemiology: Cockayne syndrome is a rare disorder worldwide, with an estimated annual incidence of approximately 1 in 200,000 to 1 in 250,000 live births in European countries. A nationwide survey in Japan estimated the incidence to be 2.77 per million births. There is no reported racial or sexual predilection for Cockayne syndrome, with a male-to-female ratio of 1:1. The disease is pan-ethnic, though specific founder mutations may be more common in certain isolated populations.

Selected references: 1. Laugel V. Cockayne Syndrome. 2000 Dec 28 [Updated 2024 Aug 29]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301516 2. Karikkineth AC, Scheibye-Knudsen M, Fivenson E, Croteau DL, Bohr VA. Cockayne syndrome: Clinical features, model systems and pathways. Ageing Res Rev. 2017 Jan;33:3-17. PMID: 27507608 3. Wilson BT, Stark Z, Sutton RE, Danda S, Ekbote AV, Elsayed SM, et al. The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care. Genet Med. 2016 May;18(5):483-93. PMID: 26270763 4. Kubota M, Ohta S, Ando A, Koyama A, Terashima H, Kashii H, et al. Nationwide survey of Cockayne syndrome in Japan: Incidence, clinical course and prognosis. Pediatr Int. 2015 Aug;57(4):639-47. PMID: 25851792 5. Figueras MFRVB, et al. Cockayne syndrome in adults: complete retinal dysfunction exploration of two case reports. Doc Ophthalmol. 2019;139(2):145-153. PMID: 30815774 6. Weidenheim KM, Dickson DW, Rapin I. Neuropathology of Cockayne syndrome: Evidence for impaired development, premature aging, and neurodegeneration. Mech Ageing Dev. 2009 Sep;130(9):619-36. PMID: 19647092